Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
16 06 2020
Historique:
pubmed: 2 6 2020
medline: 9 3 2021
entrez: 2 6 2020
Statut: ppublish

Résumé

Background There are conflicting data regarding the benefit of primary prevention implantable cardioverter-defibrillators (ICDs) in patients with diabetes mellitus and heart failure (HF) with reduced ejection fraction. We aimed to assess the comparative effectiveness of ICD placement in patients with diabetes mellitus and HF with reduced ejection fraction. Methods and Results Data were obtained from the Get With the Guidelines-Health Failure registry, linked with claims from the Centers for Medicare & Medicaid Services. We used a Cox proportional hazards model censored at 5 years with propensity score matching. Of the 17 186 patients with HF with reduced ejection fraction from the Centers for Medicare & Medicaid Services claims database (6540 with diabetes mellitus; 38%), 1677 (646 with diabetes mellitus; 39%) received an ICD during their index HF hospitalization or were prescribed an ICD at discharge. Patients with diabetes mellitus and an ICD (n=646), as compared with those without an ICD (n=1031), were more likely to be younger (74 versus 78 years of age) and have coronary artery disease (68% versus 60%). After propensity matching, ICD use among patients with diabetes mellitus, as compared with those without an ICD, was associated with a reduced risk of all-cause mortality at 5 years after HF discharge (54% versus 59%; multivariable hazard ratio, 0.73; 95% CI, 0.64-0.82;

Identifiants

pubmed: 32476539
doi: 10.1161/JAHA.119.012405
pmc: PMC7429066
doi:

Types de publication

Comparative Study Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e012405

Références

Eur J Heart Fail. 2017 Oct;19(10):1310-1320
pubmed: 28639369
J Am Heart Assoc. 2020 Jun 16;9(12):e012405
pubmed: 32476539
Am Heart J. 2009 Jun;157(6):995-1000
pubmed: 19464409
Circulation. 2013 Oct 15;128(16):1810-52
pubmed: 23741057
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
Circulation. 2015 Sep 8;132(10):923-31
pubmed: 26152709
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Circ Heart Fail. 2016 Jan;9(1):e002630
pubmed: 26758365
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Circulation. 2017 Nov 7;136(19):1772-1780
pubmed: 28877914
Eur Heart J. 2016 May 14;37(19):1526-34
pubmed: 26819227
Circulation. 2018 Sep 25;138(13):e210-e271
pubmed: 29084733
Am J Cardiol. 2018 Jul 15;122(2):255-260
pubmed: 29731121
JACC Heart Fail. 2018 Oct;6(10):813-822
pubmed: 30098964
Cardiovasc Drugs Ther. 2017 Jun;31(3):311-318
pubmed: 28536852
Eur J Heart Fail. 2018 Jun;20(6):1031-1038
pubmed: 29761861
Circ Heart Fail. 2018 Jun;11(6):e004646
pubmed: 29793934
Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):25-32
pubmed: 20123668
J Am Coll Cardiol. 2017 May 30;69(21):2606-2618
pubmed: 28545633
JAMA. 2007 Jan 3;297(1):61-70
pubmed: 17200476
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
N Engl J Med. 2009 Oct 8;361(15):1427-36
pubmed: 19812399
N Engl J Med. 2005 Jan 20;352(3):225-37
pubmed: 15659722
Diabetes Care. 2017 Dec;40(12):1763-1770
pubmed: 28986504
N Engl J Med. 2016 Sep 29;375(13):1221-30
pubmed: 27571011
N Engl J Med. 2004 Dec 9;351(24):2481-8
pubmed: 15590950
JACC Heart Fail. 2013 Jun;1(3):245-51
pubmed: 24621877

Auteurs

Abhinav Sharma (A)

Duke Clinical Research Institute Duke University School of Medicine Durham NC.
McGill University Health Centre Montreal Quebec Canada.

Jingjing Wu (J)

Duke Clinical Research Institute Duke University School of Medicine Durham NC.

Haolin Xu (H)

Duke Clinical Research Institute Duke University School of Medicine Durham NC.

Adrian Hernandez (A)

Duke Clinical Research Institute Duke University School of Medicine Durham NC.

G Michael Felker (GM)

Duke Clinical Research Institute Duke University School of Medicine Durham NC.

Sana Al-Khatib (S)

Duke Clinical Research Institute Duke University School of Medicine Durham NC.

Jennifer Green (J)

Duke Clinical Research Institute Duke University School of Medicine Durham NC.

Roland Matsouaka (R)

Duke Clinical Research Institute Duke University School of Medicine Durham NC.

Gregg C Fonarow (GC)

Ahmanson-UCLA Cardiomyopathy Center Los Angeles CA.

Jagmeet P Singh (JP)

Massachusetts General Hospital Boston MA.

Paul A Heidenreich (PA)

Veterans Affairs Palo Alto Health Care System Palo Alto CA.

Justin A Ezekowitz (JA)

Faculty of Medicine and Dentistry, Canadian VIGOUR Center University of Alberta Edmonton Alberta Canada.

Adam DeVore (A)

Duke Clinical Research Institute Duke University School of Medicine Durham NC.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH